Introduction
Heart Failure (HF) remains an urgent public health crisis. By the year 2030 an estimated 8 million people in the US will be diagnosed with HF with associated yearly medical costs >$50 billion [1] . The diagnosis of HF is primarily determined by ejection fraction and clinical presentation, with the cardinal manifestations of dyspnea, fatigue, exercise intolerance, and fluid retention. Heart failure is subclassified into two primary forms, the first HF with reduced ejection fraction (HFrEF, with ejection fraction <50%) and the second HF with preserved ejection fraction (HFpEF) where ejection fraction is maintained.
Regardless of HF subclass, the 5-year survival rate for all HF patients is less than 50%. The reader is referred to the following reviews for a comprehensive description of the clinical manifestations of HF syndromes [2] [3] [4] . The focus of this review is to examine the processes underlying aberrant cardiomyocyte Ca 2+ homeostasis in HFrEF and HFpEF, with discussion of current and emerging treatment paradigms for this complex disease.
Cardiomyocyte Ca 2+ handling mechanisms
The process whereby the ventricular cardiomyocyte transduces electric signals of the action potential into mechanical force production is well-established, and is referred to as excitation-contraction coupling (ECC) [5] .
In the healthy heart, ECC occurs via an exquisitely orchestrated series of events ( Figure 1 ) initiated by opening of voltage-gated Na + (Na V1.5 ) and Ca 2+ (Ca V1.2 ) channels with resulting cation influx and depolarization. Ca V1.2 channels within the t-tubule network localize near Ryanodine Receptors (RyR 2 ) of the Sarcoplasmic Reticulum (SR), forming a specialized microdomain termed the dyadic cleft. Within [6, 7] . Prominent possibilities include phosphorylation via PKA (Ser2808 or Ser2030), phosphorylation via CaMKII (Ser2814), oxidative/nitrosative modification, or complex combinations of these respective processes. During b 1 -receptor activation the increased trigger for CICR, enhanced activity of the RyR 2 release mechanism, and additional SR Ca 2+ content collectively contribute to a considerable increase in the amplitude of the action potential-induced cytosolic Ca 2+ transient. Indeed, the increase in peak systolic Ca 2+ is more than sufficient to overcome the PKA-induced decrease in myofilament Ca 2+ sensitivity that accompanies b 1 -receptor activation, and leads to enhanced contractile strength. Advantageously, the combination of decreased myofilament Ca 2+ sensitivity and enhanced SR Ca 2+ sequestration via SERCA also facilitates cardiomyocyte relaxation. In the healthy heart with optimal expression, localization, and function of Ca 2+ handling proteins, the cardiomyocyte is able to utilize b-adrenergic signaling to increase inotropy and lusitropy, with enhanced cardiac performance.
Cardiomyocyte Ca 2+ handling mechanisms in HFrEF
Cardiac dysfunction is intrinsic to the cardiomyocyte in HFrEF, in part due to abnormalities in cardiomyocyte Figure 2) . A frequent finding in HFrEF is a decrease in SERCA expression or a decrease in PLB phosphorylation, both of which reduce SR Ca 2+ reuptake, delay relaxation, and decrease SR Ca 2+ content [8] . Interestingly, PLB phosphorylation status in HFrEF is typically not driven by depressed kinase function, but by enhanced function of protein phosphatases [9] . Additionally, expression of NCX is increased which allows NCX to outcompete SERCA for Ca 2+ . [20] is also increased in HFpEF-related models which further enhances Ca 2+ cycling and contraction. In addition to effects on ECC, augmented Ca 2+ entry through TRPC channels [24, 27, 28] or release via IP 3 R 2 [29] are established upstream regulators of hypertrophic remodeling processes. Cardiomyocyte Ca 2+ accumulation in the absence of concomitant enhancement of SERCA activity leads to elevated diastolic Ca 2+ , Ca 2+ transients with preserved or enhanced amplitude, and slower Ca 2+ reuptake kinetics with impaired relaxation. The effect on Ca 2+ reuptake is particularly pronounced if SERCA expression decreases, as has been observed with advancing age, hypertrophy, obesity, diabetes, and renal disease. Ca 2+ sequestration rate may be further reduced by glycative [30] or oxidative [31] modification of SERCA, depending on etiology. The inability of SERCA to expeditiously resequester Ca 2+ becomes particularly evident at elevated stimulation frequencies, which may in part explain the chronotropic intolerance of the myocardium and reduced exercise capacity of HFpEF patients. In many animal models of HFpEF, the aforementioned adaptive phase transitions into cardiac decompensation/ cardiomyopathy and a HFrEF-like phenotype with depressed cardiomyocyte Ca 2+ transients and contractility [22 ] . However, the clinical relevance of this transition remains unclear, as clinical investigations suggest HFpEF and HFrEF are independent patient populations originating from distinct disease processes [4] .
Therapeutic interventions to normalize cardiomyocyte Ca 2+ handling
Cardiac glycosides: Digitalis compounds (cardiac glycosides) have been used since the 18th century to treat HF. By partially inhibiting the Na + /K + -ATPase, glycosides elevate intracellular Na + , which extends the brief period of the action-potential when NCX 'reverses' and contributes to Ca 2+ influx ( Figure 3 , Table 1 ). Glycosides may also directly [32] or indirectly [33] activate RyR 2 and facilitate SR Ca 2+ release. While such actions may further augment contractility they also likely contribute to the arrhythmogenic side-effects of cardiac glycosides. Lowdose digoxin has been evaluated in placebo trials [34] and remains in clinical use in HFrEF.
Istaroxime is a dual-action steroid derivative that increases contractility in a manner similar to cardiac glycosides. However, istaroxime also enhances SERCA Ca 2+ reuptake and relaxation, and is less arrhythmogenic than digoxin [35] . While initial clinical trials suggest istaroxime is effective in HFrEF due to its singular ability to enhance both contraction and relaxation [36] , it has yet to progress into clinical use.
From b-agonists to b-blockers: Inotropic approaches which utilize the endogenous b 1 -adrenergic signal transduction machinery (e.g., b 1 -receptor agonists, phosphodiesterase (PDE) 3 inhibitors) are highly effective in enhancing contractility. However, such agents produce negative long-term outcomes in HFrEF, in part due to increased myocardial oxygen demand [37, 38] . The augmented Ca 2+ influx following b 1 -receptor activation, if sustained, also contributes to Ca 2+ -dependent cardiomyocyte necrosis [39] and acceleration of adverse remodeling [40] . Accumulation of cardiomyocyte and SR Ca 2+ is also detrimental in HFrEF due to leaky RyR 2 channels, which predisposes the cardiomyocyte to diastolic SR Ca 2+ release, DADs, and arrhythmia. Thus, while inotropic strategies are still used clinically to restore cardiac output in acute cardiogenic shock, long-term use in HFrEF is contraindicated. The failure of inotropic therapies in clinical trials led to the reciprocal approach of preventing b 1 -adrenergic signaling, and b-blockers are currently a standard first-line treatment approach in HFrEF. Carvedilol and its structural analogs have also been shown to prevent diastolic SR Ca 2+ release by stabilizing RyR 2 [41] , which serves as an additive anti-arrhythmic effect of this particular b-blocker.
Ranolazine: Intracellular Na + overload is prevalent in HF, in part due to increased activity of slowly-inactivating Na + channels (late Na + current). Ranolazine is an inhibitor of the late Na + current, which reduces Na + accumulation and shifts the electrochemical gradient of NCX towards greater Ca 2+ extrusion and a reduction in diastolic Ca 2+ [42] .
PDE5/9 inhibitors: Levels of cGMP and downstream
Protein Kinase G (PKG) activity are reduced in HFpEF patients [43] , making inhibitors of PDEs that selectively degrade cGMP appealing treatments in HFpEF [44] . By phosphorylating Ca 2+ channels (Ca v1.2 and TRPC6) PKG inhibits Ca 2+ influx and decreases hypertrophic gene transcription. PKG phosphorylation also reduces cardiomyocyte stiffness and produces lusitropic effects on relaxation. Despite highly encouraging preclinical results, the PDE5 inhibitor sildenafil did not show benefit in HFpEF patients [45 ] . [29] and TRPC3/6 [50] . Excessive Ca 2+ flux through these respective channels also associates with diastolic SR Ca 2+ leak and arrhythmogenesis
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www.sciencedirect.com Current Opinion in Pharmacology 2017, 33:17-26 handling proteins a feasible therapy in HFrEF [52, 53] . Most notably, AAV-mediated SERCA overexpression counteracts the decrease in SERCA pumping ability found in animal models of HFrEF, and Phase 2 trials of AAV-1.SERCA2a (Mydicar) were encouraging [54, 55] . Unfortunately, Mydicar did not provide benefit in HFrEF patients in a recent, larger Phase 2b clinical trial [56 ] . Additional AAV gene therapy approaches that target cardiomyocyte Ca 2+ handling include overexpression of the Ca 2+ sensor protein S100A1, small ubiquitinlike modifier 1 (SUMO-1), a peptide inhibitor to prevent downregulation of b-adrenoreceptors (bARKct), protein phosphatase 1 inhibitor-1, and adenylyl cyclase 6. AAVmediated transfer of micro-RNAs to alter gene transcription pathways in the setting of HF represent alternative approaches with therapeutic potential [57 ,58] .
Conclusion
Therapies which target cardiomyocyte Ca 2+ handling mechanisms are effective in HFrEF, where cardiac dysfunction is intrinsic to the cardiomyocyte. Cardiac dysfunction in HFpEF is complex and in many cases extrinsic to the cardiomyocyte. Nevertheless, cardiomyocyte Ca 2+ handling processes are altered in HFpEF, and current phenotype-specific therapies may exert secondary beneficial effects on cardiomyocyte Ca 2+ handling processes and disease progression. 
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